Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
With its demonstrated benefits on blood sugar and cholesterol, this medication could reduce the risks associated with obesity, such as type 2 diabetes and heart disease
doi: 10.3389/fvets.2023.1147024 32
Amgens long-acting monthly obesity therapy MariTide (maridebart cafraglutide, formerly AMG 133) demonstrated substantial and sustained weight loss in a Phase II trial, with patients achieving an average of 20% weight loss without a plateau, along with cardiometabolic improvements, over 52 weeks
At the time, she was already eating a healthy diet, and her doctor thought this medication could make it easier for her to lose weight
